Advice

In the absence of a submission from the holder of the marketing authorisation:

vismodegib (Erivdege ®) is not recommended for use within NHS Scotland.

Indication under review: treatment of adult patients with:

  • symptomatic metastatic basal cell carcinoma
  • locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice89KB (PDF)

Download

Medicine details

Medicine name:
vismodegib (Erivedge)
SMC ID:
924/13
Indication:
Treatment of adult patients with: symptomatic metastatic basal cell carcinoma & locally advanced basal cell carcinoma; inappropriate for surgery or radiotherapy
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
07 October 2013